Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT
Primary result · MIResult — go to the resultHazard ratio 0.69 95% CI 0.58–0.81Authors' conclusion
IPE significantly reduced MI across most subtypes and sizes in statin-treated patients with elevated triglycerides at increased cardiovascular risk.
Study context
- Population
- Statin-treated patients with established CVD or diabetes and moderate hypertriglyceridemia
- Comparison
- Icosapent ethyl (IPE) 4g daily vs placebo
- Primary endpoint
- MI incidence
- Follow-up
- 5.7 years
Methodological detailsphase 3b, double-blind, multicentre
- Phase 3b
- Double-blind
- Multicentre
Primary result
MI · 5.7 years
Hazard ratio
0.69
95% CI 0.58–0.81
P < 0.0001
By group
IPE vs Placebo
HR 0.69 (95% CI 0.58–0.81); P < 0.0001
As reported in the abstract
Further findings
| Outcome | IPE | Placebo | HR (95% CI) | P value | |
|---|---|---|---|---|---|
| STEMI | 2.7% | 3.9% | 0.60 (0.44–0.81) | P = 0.0008 | |
| NSTEMI | 5.9% | 7.8% | 0.73 (0.60–0.89) | P = 0.001 | |
| Fatal and nonfatal MIFatal MI | 0.55 (0.30–1.01) | P = 0.05 | |||
| Fatal and nonfatal MINonfatal MI | 0.70 (0.59–0.82) | P < 0.0001 | |||
| 0.20.5125Hazard ratio (log scale) |
Myocardial infarction (MI) by size (multiples of troponin ULN)
- IPE reduced most MIs; protective effect higher for larger MIs
- P < 0.0001
Spontaneous MI and MI-related complications
- Reductions with IPE
Safety
Serious bleeding, AF or flutter, adverse events (patients who developed MI)
- No significant increase with IPE
Original publication
Benefit of icosapent ethyl across types and sizes of myocardial infarction in REDUCE-IT. Eur J Prev Cardiol. Published 22 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →